Pre-existing antibody-mediated adverse effects prevent the clinical development of a bacterial anti-inflammatory protein

• Main Authors: Angelino T. Tromp (Author), Yuxi Zhao (Author), Ilse Jongerius (Author), Erik C. J. M. Heezius (Author), Pauline Abrial (Author), Maartje Ruyken (Author), Jos A. G. van Strijp (Author), Carla J. C. de Haas (Author), András N. Spaan (Author), Kok P. M. van Kessel (Author), Thomas Henry (Author), Pieter-Jan A. Haas (Author)
• Format: Book
• Published: The Company of Biologists, 2020-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Bacterial pathogens have evolved to secrete strong anti-inflammatory proteins that target the immune system. It was long speculated whether these virulence factors could serve as therapeutics in diseases in which abnormal immune activation plays a role. We adopted the secreted chemotaxis inhibitory...